FDG-Avid Hurthle Cell Thyroid Adenoma.
Yu R, Auerbach MS.
Clin Nucl Med. 2019 Sep;44(9):752-753. doi: 10.1097/RLU.0000000000002617.
Hurthle Cell Thyroid Adenoma Showing Avid Uptake on 18F-PSMA-1007 PET/CT.
Tang K, Wang Z, Lin J, Zheng X.
Clin Nucl Med. 2020 Mar;45(3):223-224. doi: 10.1097/RLU.0000000000002873.
Genetics, Diagnosis, and Management of Hurthle Cell Thyroid Neoplasms.
McFadden DG, Sadow PM.
Front Endocrinol (Lausanne). 2021 Jun 10;12:696386. doi: 10.3389/fendo.2021.696386. eCollection 2021.
Unraveling Hurthle cell lesions of the thyroid using molecular findings.
Wong KS.
Cancer Cytopathol. 2022 Jun;130(6):405-406. doi: 10.1002/cncy.22567. Epub 2022 Mar 14.
Hurthle cell lesions of the thyroid: Progress made and challenges remaining.
Wong KS, Angell TE, Barletta JA, Krane JF.
Cancer Cytopathol. 2021 May;129(5):347-362. doi: 10.1002/cncy.22375. Epub 2020 Oct 27.
Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma: A Review and Multidisciplinary 2023 Update.
Bischoff LA, Ganly I, Fugazzola L, Buczek E, Faquin WC, Haugen BR, McIver B, McMullen CP, Newbold K, Rocke DJ, Russell MD, Ryder M, Sadow PM, Sherman E, Shindo M, Shonka DC Jr, Singer MC, Stack BC Jr, Wirth LJ, Wong RJ, Randolph GW.
JAMA Otolaryngol Head Neck Surg. 2024 Mar 1;150(3):265-272. doi: 10.1001/jamaoto.2023.4323.
Hurthle cell carcinoma.
Yutan E, Clark OH.
Curr Treat Options Oncol. 2001 Aug;2(4):331-5. doi: 10.1007/s11864-001-0026-4.
Epigenomics in Hurthle Cell Neoplasms: Filling in the Gaps Towards Clinical Application.
Canberk S, Lima AR, Pinto M, Soares P, Máximo V.
Front Endocrinol (Lausanne). 2021 May 24;12:674666. doi: 10.3389/fendo.2021.674666. eCollection 2021.
Short Review: Genomic Alterations in Hurthle Cell Carcinoma.
Ganly I, McFadden DG.
Thyroid. 2019 Apr;29(4):471-479. doi: 10.1089/thy.2019.0088.
Hurthle cell tumor.
Chen HY, Benjamin LB, Chen MF.
Int Surg. 1996 Apr-Jun;81(2):168-70.
